MLTX MoonLake Immunotherapeutics
$11.82▲ +0.08%
Healthcare
Other
Volume 431.4K
Avg Volume (10D) 1.95M
Key Metrics & Fundamentals
Market Cap
$1.01B
P/E Ratio
–
Div Yield
0.00%
52W Range
9.37 - 23.29
% vs 50 MA
-8.14%
% vs 200 MA
-28.76%
RSI-14
52.3
MACD Histogram
+0.3300
Beta (1Y vs SPY)
1.37
Free Cash Flow
-$55.56M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$57.89M
COGS
–
Operating Exp
$61.66M
Operating Income
-$61.66M
EBIT
-$61.66M
Pretax Income
-$61.72M
Net Income
-$61.81M
EPS (Diluted)
-0.84
Price & Volume History
Loading chart…
Recent News
MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
Simply Wall St. · Oct 25, 2026 6:15 AM ET
MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
Simply Wall St. · Oct 24, 2026 10:07 PM ET
AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS Trial
TIKR · Oct 22, 2026 4:17 PM ET
MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
TIKR · Oct 22, 2026 1:17 PM ET
MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
MT Newswires · Oct 16, 2026 11:35 AM ET
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
MT Newswires · Oct 5, 2026 11:26 AM ET
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
GlobeNewswire · Sep 21, 2026 1:00 PM ET
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
Stocktwits · Sep 11, 2026 1:48 PM ET
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
Stocktwits · Aug 10, 2026 9:24 AM ET
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
MT Newswires · Aug 10, 2026 9:08 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See MLTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.